Zinc containing compositions for anti-viral use
OwnerJeffrey B. Smithinventor
Life of this patent
Estimating the term…
Abstract
One aspect of the invention relates to anti-viral composition containing at least one zinc compound and at least one phenolic antioxidant (and optionally other ingredients such as at least one analgesic) at least one hydrocarbyl containing compound, and water. Another aspect of the invention relates to a method of treating lesionous symptoms of a viral infection involving applying an effective amount of the zinc containing anti-viral composition to the lesions.
Claims22
A zinc containing anti-viral composition, comprising:
- about 0.005% by weight or more and about 20% by weight or less of at least one zinc compound;
- about 0.001% by weight or more and about 20% by weight or less of at least one antioxidant selected from the group consisting of butylated hydroxytoluene;
- 2(3)-tert-butyl-4-methoxyphenol;
- 2,6-di-tert-butyl-4-cumylphenol;
- 2,6-di-tert-butyl-4-nonylphenol;
- 2,6-dicumylphenol;
- 2,6-di-tert-butyl-4-isooctylphenol;
- 4,4′-methylene-bis(2,6-di-tert-butylphenol);
- and 2,2′-methylene-bis(4-methyl-6-tert-butylphenol);
- about 0.1% by weight or more and about 50% by weight or less of at least one analgesic;
- about 5% by weight or more and about 80% by weight or less of at least one hydrocarbyl containing compound;
- and
- about 0 1% by weight or more and about 60% by weight or less of water.
A method of treating lesionous symptoms of a viral infection, comprising:
- applying an effective amount of a zinc containing composition to the lesions, the zinc containing composition comprising about 0.005% by weight or more and about 20% by weight or less of at least one zinc compound, about 0.001% by weight or more and about 20% by weight or less of at least one antioxidant selected from the group consisting of butylated hydroxytoluene;
- 2(3)-tert-butyl-4-methoxyphenol;
- 2,6-di-tert-butyl-4-cumylphenol;
- 2,6-di-tert-butyl-4-nonylphenol;
- 2,6-dicumylphenol;
- 2,6-di-tert-butyl-4-isooctylphenol;
- 4,4′-methylene-bis(2,6-di-tert-butylphenol);
- and 2,2′-methylene-bis(4-methyl-6-tert-butylphenol), about 0.1% by weight or more and about 50% by weight or less of at least one analgesic, about 5% by weight or more and about 80% by weight or less of at least one hydrocarbyl containing compound, and about 0.1% by weight or more and about 60% by weight or less of water.
A method for the topical treatment of herpes infections in humans, comprising applying to an area of skin or mucous membrane infected with herpes an effective amount of a zinc containing composition comprising about 0.01% by weight or more and about 10% by weight or less of at least one zinc salt, about 0.005% by weight or more and about 10% by weight or less of at least one antioxidant selected from the group consisting of butylated hydroxytoluene;
- 2(3)-tert-butyl-4-methoxyphenol;
- 2,6-di-tert-butyl-4-cumylphenol;
- 2,6-di-tert-butyl-4-nonylphenol;
- 2,6-dicumylphenol;
- 2,6-di-tert-butyl-4-isooctylphenol;
- 4,4′-methylene-bis(2,6-di-tert-butylphenol);
- and 2,2′-methylene-bis(4-methyl-6-tert-butylphenol), about 1% by weight or more and about 40% by weight or less of at least one analgesic, about 5% by weight or more and about 80% by weight or less of at least two hydrocarbyl containing compounds, and about 0.1% by weight or more and about 60% by weight or less of water.
A method of treating lesionous symptoms of a viral infection, comprising:
- applying an effective amount of a zinc containing composition to the lesions, the zinc containing composition comprising about 0.005% by weight or more and about 20% by weight or less of at least one zinc compound, about 0.001% by weight or more and about 20% by weight or less of at least one phenolic antioxidant, about 0.1% by weight or more and about 50% by weight or less of at least one analgesic, about 5% by weight or more and about 80% by weight or less of at least one hydrocarbyl containing compound, and about 0.1% by weight or more and about 60% by weight or less of water;
- and
- adhering to a low arginine diet.
A method for the topical treatment of herpes infections in humans, comprising:
- applying to an area of skin or mucous membrane infected with herpes an effective amount of a zinc containing composition comprising about 0.01% by weight or more and about 10% by weight or less of at least one zinc salt, about 0.005% by weight or more and about 10% by weight or less of at least one phenolic antioxidant, about 1% by weight or more and about 40% by weight or less of at least one analgesic, about 5% by weight or more and about 80% by weight or less of at least two hydrocarbyl containing compounds, and about 0.1% by weight or more and about 60% by weight or less of water;
- and
- adhering to a low arginine diet and a high lysine diet.
Dependencies are inferred from the claim text.